4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyramide | 1233337-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyramide
• 英文别名: 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]butanamide
• CAS: 1233337-46-6
• 化学式: C₁₇H₁₇F₃N₄O₂S
• 分子量: 398.409
• InChiKey: YRDDIJIKMMSBNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  123
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)butanoic acid 在 氯甲酸乙酯 、 三乙胺 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以55%的产率得到4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]butyramide
  参考文献：
  名称：

  Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists

  摘要：

  A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.03.036

文献信息

• Structure–activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists
  作者：Hitoshi Yoshino、Haruhiko Sato、Kazutaka Tachibana、Takuya Shiraishi、Mitsuaki Nakamura、Masateru Ohta、Nobuyuki Ishikura、Masahiro Nagamuta、Etsuro Onuma、Toshito Nakagawa、Shinichi Arai、Koo-Hyeon Ahn、Kyung-Yun Jung、Hiromitsu Kawata

  DOI：10.1016/j.bmc.2010.03.036

  日期：2010.5

  A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently. (c) 2010 Elsevier Ltd. All rights reserved.